Search results for "Highlights"


 
Results 1 - 10 of about 468 for "Highlights".
Sort by: Relevance | Newest | Oldest

Review calls for increased measurement, treatment of diabetes distress

An analysis of six studies found that an average of 78.3% of people with diabetes had at least some clinically relevant diabetes distress-related problems and that a commonly used scale does not capture most patients with distress.
https://diabetes.acponline.org/archives/2024/11/08/3.htm
8 Nov 2024

Dexamethasone not associated with survival benefit in inpatients with COVID-19, diabetes

Patients with diabetes and severe COVID-19 who were treated with dexamethasone had slower time to clinical recovery than propensity-matched patients who didn't get dexamethasone, and steroid treatment did not improve mortality, a retrospective study found.
https://diabetes.acponline.org/archives/2024/11/08/2.htm
8 Nov 2024

Subscribe

ACP Diabetes Monthly delivers a monthly summary of news about diabetes, including the latest research, clinical guidelines, and FDA drug actions.
https://diabetes.acponline.org/subscribe/index.html

Short-term insulin followed by oral drugs provided glucose control in new type 2 diabetes

Patients with a new diagnosis of type 2 diabetes and an HbA1c level of 8.5% or greater significantly lowered their HbA1c levels if they took insulin for two to three weeks before switching to linagliptin, metformin, or both, a randomized trial in China found.
https://diabetes.acponline.org/archives/2024/11/08/1.htm
8 Nov 2024

Report and study highlight risk of heart failure in patients with diabetes

The American Diabetes Association made recommendations on diagnosing and treating heart failure in patients with diabetes, and a study found increased risk of progression to clinical heart failure in those with an HbA1c level of 7% or above.
https://diabetes.acponline.org/archives/2022/06/10/1.htm
10 Jun 2022

Spotlight on liver health in diabetes

A review compared liver outcomes for most classes of diabetes drugs, while a retrospective study looked at glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors head to head. Another study offered a new score for metabolic dysfunction-associated steatotic liver disease.
https://diabetes.acponline.org/archives/2024/10/11/5.htm
11 Oct 2024

Metformin linked with lower delirium risk in older patients with type 2 diabetes

There was a dose-response relationship between metformin and delirium in those ages 65 years and older, with higher cumulative and daily doses of the medication linked with lower delirium risk, a cohort study in Taiwan indicated.
https://diabetes.acponline.org/archives/2024/10/11/3.htm
11 Oct 2024

Diabetes-related foot ulcers associated with high short-term mortality rates

In patients with a new diabetes-related foot ulcer, mortality rates were 4.2%, 8.2%, and 14.4% at 12, 26, and 52 weeks, and even higher rates were seen with cardiovascular or renal comorbidities or older age, a study in England and Wales found.
https://diabetes.acponline.org/archives/2024/10/11/2.htm
11 Oct 2024

Inpatients on insulin effectively used personal CGMs during hospitalization

Most patients and nurses reported satisfaction with a protocol that allowed use of personal continuous glucose monitors (CGMs) in lieu of fingerstick blood glucose tests, a retrospective single-center study reported.
https://diabetes.acponline.org/archives/2024/09/13/2.htm
13 Sep 2024

Hyperkalemia may be less common with GLP-1s than DPP-4s

Patients with type 2 diabetes who were taking glucagon-like peptide-1 (GLP-1) receptor agonists had lower rates of hyperkalemia than those taking dipeptidyl peptidase-4 (DPP-4) inhibitors and were more likely to continue renin-angiotensin system inhibitors over the long term, a cohort study found.
https://diabetes.acponline.org/archives/2024/09/13/3.htm
13 Sep 2024

Result Page: Prev   1   2   3   4   5   6   7   8   9   10   Next